RNA-Editing Therapy Moves Toward a Pivotal Trial: Wave Says FDA Supports Two-Year Study Path for WVE-006

For patients with alpha-1 antitrypsin deficiency (AATD), the lungs and liver may suffer different forms of damage from the same genetic defect. Restoring the body’s ability to produce normal protein could offer a way to treat both organs. On October 1, Wave Life Sciences announced that feedback from a meeting with the U.S. Food and Drug Administration (FDA) supported key elements of the proposed path to approval for its RNA-editing candidate WVE-006, providing clearer direction for the next stage of research.

According to the company, the planned single registrational trial will run for two years and is intended to support full approval. An interim analysis at one year could provide a basis for seeking accelerated approval based on AATD biomarker results. If the study results meet the requirements, subsequent data from the same trial could support full approval without a separate confirmatory trial. However, this represents progress in discussions about the study path; it does not mean the FDA has approved the drug or guarantee that a future application will be approved.

The disease involves abnormalities in the SERPINA1 gene. Normal alpha-1 antitrypsin protects the lungs, but in patients with two copies of the Z variant, known as Pi*ZZ, abnormal Z-AAT protein tends to remain in the liver, while insufficient functional protein also damages the lungs. Existing intravenous protein augmentation therapy can replenish AAT but cannot address the risks posed by abnormal protein accumulation in the liver. This is the gap the new therapy seeks to bridge.

WVE-006 is administered by subcutaneous injection and is designed to use RNA editing to correct the single-base abnormality associated with Pi*ZZ, enabling cells to produce normal M-AAT while reducing the production of abnormal Z-AAT. This approach acts on RNA and does not rewrite genomic DNA. Whether it can therefore sustainably reduce the burden on the liver and protect the lungs still requires validation in patient studies.

Another development concerns measurement tools. Wave said the FDA supported using the company’s existing liquid chromatography–mass spectrometry (LC-MS) method in the registrational study to measure normal M-AAT and abnormal Z-AAT separately. BioPharm International noted that the announcement did not specify the expected enrollment, primary efficacy endpoints, or which biomarkers would be used in the one-year interim analysis. Support for this testing method therefore cannot be directly interpreted as FDA acceptance of a particular protein measurement as a basis for accelerated approval.

WVE-006 is currently still being evaluated in the Phase 1b/2a, open-label RestorAATion-2 trial. BioPharm International cautioned that existing results primarily consist of protein measurements from a small study and have not established clinical benefits for the lungs or liver. Changes in protein composition in the intended direction provide clues about the drug’s activity, but further follow-up is still needed to demonstrate improvement in patients’ disease.

RTTNews reported on the same day that Wave expects to release data from the monthly 600-milligram multiple-dose cohort in the fourth quarter of 2026. The company currently describes the therapy as generally safe and well tolerated, with no reported hepatotoxicity. These descriptions remain observations from an early-stage trial and cannot rule out longer-term or rare risks. Beyond the next set of data, how the pivotal trial connects protein changes with health benefits that patients actually experience will determine how far this path to approval can progress.